Establish Bone Repair Biomaterials Database via FDA Scraping & Clinical Trial Aggregation
- Organization
- NSF SBIR Phase II commercialization plan requirement (mandates competitive analysis without providing tools)
- Sector
- SBIR-funded biomaterial companies needing comparative efficacy data for Phase II applications
- Location
- Location unspecified
Source reference
Executive summary
Current state
NSF awarded $305K SBIR Phase I funding to CYTROGEN for Gelatrix, a light-curable bone adhesive, creating a research-funded entity with technical validation capital but zero commercial infrastructure, manufacturing partnerships, or market access pathways.
Market catalyst
NSF requires a commercialization plan for Phase II proposals but provides no standardized database for competitive analysis. CYTROGEN and hundreds of other SBIR biomaterial companies must individually research FDA submissions, clinical trials, and competitive products—a repetitive, inefficient process ripe for centralization.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.